Anemia affects the quality of life of CKD patients and increases the risk of CKD progression. we conducted a real-world study on patients with anemia in CKD to analyze the disease characteristics and treatment in Chinese patients with CKD-anemia.
Anemia adversely affects the quality of life of CKD patients and increases the risk of CKD progression. This study utilize data from approximately 20 medical centers across China. It aims to: 1. Analyze the disease characteristics, current diagnostic and treatments in Chinese patients with CKD-anemia. 2. Evaluate the safety and efficacy profiles of different drugs used for CKD-anemia. 3. Explore the direct medical costs associated with CKD-anemia management within real-world clinical practice in China.
Study Type
OBSERVATIONAL
Enrollment
20,000
First Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China
Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China.
Disease characteristics and current treatments of anemia in chronic kidney disease (CKD) patients in China will beperformed to assess the proportions of CKD primary diseases, distribution of CKD stages, baseline Hb level distribution, and proportion of anti-anemia medication usage.
Time frame: 20230101-20241231
Incidence of Adverse Events according to CTCAE 5.0 (Safety profile of different anemia medications in CKD patients with anemia.)
An analysis will be performed to assess the safety according to CTCAE 5.0 .
Time frame: 20230101-20241231
Analyze the efficacy of different anemia drugs in CKD patients with anemia.
Use the hemoglobin level to analyze the efficacy of different anemia drugs in CKD patients with anemia.
Time frame: 20230101-20241231
Explore the economic burden of anemia in CKD patients
Use the annual cost to explore the direct economic burden of anemia in CKD patients.
Time frame: 20230101-20241231
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.